Cathepsin S inhibitors: WO2010070615

Other OA: closed
View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-31 ⓘ

Medivir describes dipeptide-derived alpha-ketoamides as selective cathepsin S inhibitors for potential treatment of autoimmune diseases, multiple sclerosis, rheumatoid arthritis, endometriosis, and chronic pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This article evaluates a patent application of the company Medivir (SE/UK) describing the synthesis of dipeptide-derived α-ketoamides containing a propylene glycine moiety in P1 as selective inhibitors of cathepsin S for the potential treatment of various systemic human diseases such as several autoimmune diseases, MS, rheumatoid arthritis, endometriasis and chronic pain. The claims of the patent are discussed in light of recent results in the field of cathepsin S research.

My notes (saved in your browser only)

MeSH descriptors

Cathepsins Cyclobutanes Oligopeptides Patents as Topic Protease Inhibitors Cathepsins Cyclobutanes Cyclobutanes Cyclobutanes Oligopeptides Oligopeptides Oligopeptides Protease Inhibitors Protease Inhibitors Protease Inhibitors

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
pubmed
last seen: 2026-10-08T21:08:28.697392+00:00
unpaywall
last seen: 2026-11-20T08:37:33.920708+00:00